Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation.
作者信息
Fender Anke C, Dobrev Dobromir
机构信息
Institute of Pharmacology, Medical Faculty, University Duisburg-Essen, Germany.
出版信息
Int J Cardiol Heart Vasc. 2020 Apr 10;27:100487. doi: 10.1016/j.ijcha.2020.100487. eCollection 2020 Apr.
Abstract
摘要
相似文献
1
Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation.不良影响：与直接口服抗凝剂相比，房颤患者使用维生素K拮抗剂时患骨质疏松症的风险更高。
Int J Cardiol Heart Vasc. 2020 Apr 10;27:100487. doi: 10.1016/j.ijcha.2020.100487. eCollection 2020 Apr.
2
Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists.心房颤动的死亡率：阿司匹林、维生素 K 和非维生素 K 拮抗剂的作用。
Int J Clin Pharm. 2019 Dec;41(6):1536-1544. doi: 10.1007/s11096-019-00916-1. Epub 2019 Oct 8.
3
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
4
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.真实世界证据比较非瓣膜性心房颤动的口服抗凝药物：系统评价和网络荟萃分析。
Future Cardiol. 2022 May;18(5):393-405. doi: 10.2217/fca-2021-0120. Epub 2022 Apr 1.
5
Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.使用非维生素 K 拮抗剂口服抗凝剂或华法林的房颤患者的骨质疏松风险。
J Am Heart Assoc. 2020 Jan 21;9(2):e013845. doi: 10.1161/JAHA.119.013845. Epub 2020 Jan 10.
6
Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?对于肥厚型心肌病合并心房颤动的患者，直接口服抗凝剂能否替代维生素K拮抗剂？
Int J Cardiol. 2018 Apr 1;256:39. doi: 10.1016/j.ijcard.2017.10.113.
7
Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.骨质疏松性骨折在接受常规抗凝剂与直接抗凝剂治疗的心房颤动患者中的比较。
J Am Coll Cardiol. 2019 Oct 29;74(17):2150-2158. doi: 10.1016/j.jacc.2019.08.1025.
8
Warfarin compared with non-vitamin K antagonist oral anticoagulants in subjects with liver disease and atrial fibrillation: A meta-analysis.在患有肝病和心房颤动的受试者中，华法林与非维生素K拮抗剂口服抗凝剂的比较：一项荟萃分析。
Int J Clin Pract. 2021 Oct;75(10):e14585. doi: 10.1111/ijcp.14585. Epub 2021 Jul 10.
9
Outcomes of cardiac surgery with left atrial appendage occlusion versus no Occlusion, direct oral Anticoagulants, and vitamin K Antagonists: A systematic review with Meta-analysis.左心耳封堵术与未封堵、直接口服抗凝药及维生素K拮抗剂用于心脏手术的结局：一项Meta分析的系统评价
Int J Cardiol Heart Vasc. 2022 Apr 26;40:100998. doi: 10.1016/j.ijcha.2022.100998. eCollection 2022 Jun.
10
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.非维生素 K 拮抗剂口服抗凝剂与华法林在 III 期心房颤动试验中的净临床获益。
Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034. Epub 2015 Apr 22.
引用本文的文献
1
Recent highlights on thrombosis and hemostasis from the International Journal of Cardiology: Heart & Vasculature.《国际心脏病学杂志：心脏与血管》关于血栓形成与止血的近期亮点。
Int J Cardiol Heart Vasc. 2022 Dec;43:101145. doi: 10.1016/j.ijcha.2022.101145. Epub 2022 Nov 5.
本文引用的文献
1
Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation.非瓣膜性心房颤动患者中直接口服抗凝剂与华法林相比与骨质疏松症风险的关联。
Int J Cardiol Heart Vasc. 2020 Feb 16;27:100484. doi: 10.1016/j.ijcha.2020.100484. eCollection 2020 Apr.
2
Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.使用非维生素 K 拮抗剂口服抗凝剂或华法林的房颤患者的骨质疏松风险。
J Am Heart Assoc. 2020 Jan 21;9(2):e013845. doi: 10.1161/JAHA.119.013845. Epub 2020 Jan 10.
3
Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.亚洲房颤合并颅内出血史患者的口服抗凝治疗。
Stroke. 2020 Feb;51(2):416-423. doi: 10.1161/STROKEAHA.119.028030. Epub 2019 Dec 9.
4
Drug-induced Reduction of Gamma Carboxylation in Osteocalcin: What is the Fallback?药物诱导骨钙素γ羧化作用降低：备用机制是什么？
Cureus. 2019 Aug 28;11(8):e5504. doi: 10.7759/cureus.5504.
5
Warfarin-Induced Fractures in Atrial Fibrillation?华法林所致心房颤动骨折？
J Am Coll Cardiol. 2019 Oct 29;74(17):2159-2161. doi: 10.1016/j.jacc.2019.08.1026.
6
One for all and all for one? The dilemma of optimal management of atrial fibrillation with cardiac co-morbidities.
Int J Cardiol. 2020 Jan 15;299:175-176. doi: 10.1016/j.ijcard.2019.10.010. Epub 2019 Oct 7.
7
Anticoagulation in difficult settings RELOADed: Evidence for applicability of direct oral anticoagulants in patients with atrial fibrillation, renal impairment and cancer.复杂情况下的抗凝治疗：重新加载（RELOAD）：直接口服抗凝剂在房颤、肾功能不全和癌症患者中应用的证据
Int J Cardiol Heart Vasc. 2019 May 11;23:100374. doi: 10.1016/j.ijcha.2019.100374. eCollection 2019 Jun.
8
Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?双重困境：新的试验能告诉我们如何治疗患有心房颤动和冠状动脉疾病的患者吗？
Int J Cardiol Heart Vasc. 2019 May 7;23:100369. doi: 10.1016/j.ijcha.2019.100369. eCollection 2019 Jun.
9
Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials.维生素 K 对成年人骨密度和骨折的影响：一项更新的随机对照试验系统评价和荟萃分析。
Osteoporos Int. 2019 Aug;30(8):1543-1559. doi: 10.1007/s00198-019-04949-0. Epub 2019 May 10.
10
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.直击要害：口服抗凝剂的多效抗心律失常作用。
Pharmacol Res. 2019 Jul;145:104257. doi: 10.1016/j.phrs.2019.104257. Epub 2019 May 2.
Zotero 插件